The combination of @entity416 and @entity2600 in treating @entity1487 - and XXXX -pretreated @entity14 .

@entity1 @entity901 @entity137 @entity2600 @entity416 @entity417 @entity3136 @entity294 @entity1398 @entity8566 @entity14 @entity1487 @entity1209
PURPOSE: Since the combination of @entity416 and @entity2600 has successfully been used as a first-line treatment in @entity14 ( @entity14 ), we expected promising results when given as a second-line treatment to metastatic colorectal @entity1 who had been pretreated with @entity1487 and @entity901 . METHODS: Thirty-three @entity14 @entity1 participated in this study and received an oral dose of 1,000 mg/m(2 ) @entity416 twice daily on days 1-14 and a dose of 100 mg/m(2) @entity2600 infused over 90 min on days 1 and 8, every 3 weeks. RESULTS: The overall response rate in intent-to-treat was 33.3% (95% CI, 21.5-58.3%), including one complete response (3.0%) and ten partial responses (30.3%); 12 @entity1 (36.4%) had disease stabilization and only 9 (27.3%) progressed. The median time to progression was 6.7 months (95% CI, 4.8-8.6 months). After a median follow-up time of 12 months, nine @entity1 (27.3%) were still alive with metastatic disease. The median response duration for all @entity1 was 6.7 months (95% CI, 3.9-9.5 months) and the median overall survival was 13.4 months (95% CI, 11.0-15.8 months) with a 1-year survival rate of 55.4%. Myelosuppression was commonly observed; NCI-CTC (v 2.0) grade 3/4 @entity1398 , however, occurred in eight (24%) @entity1 and grade 3 @entity417 was seen in one @entity1 (3%). The most common (grade 3/4) non-hematological @entity137 was @entity294 (15%) and the other severe grade 3/4 @entity137 included @entity1209 in one @entity1 (3%), @entity3136 in one @entity1 (3%), @entity8566 in one @entity1 (3%). CONCLUSIONS: The combination of @entity416 and @entity2600 is an effective and well-tolerated regimen for second-line treatment of @entity14 . However, further phase III trials are required to clarify its use in the treatment of metastastic @entity14 @entity1 who have been pretreated with @entity1487 and @entity901 .
